Aerie Pharma (AERI) Misses Q3 EPS by 35c

Aerie Pharma (NASDAQ: AERI) reported Q3 EPS of ($1.73), $0.35 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $5.88 million.

As of September 30, 2018, Aerie had cash, cash equivalents and investments of $236.0 million.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy